Literature DB >> 1637663

Assessment of morbidity from complete axillary dissection.

D Ivens1, A L Hoe, T J Podd, C R Hamilton, I Taylor, G T Royle.   

Abstract

The importance of axillary dissection as part of the primary surgical procedure in the treatment of operable cases of carcinoma of the breast is established. The morbidity of this procedure, however, is less well documented. A study of 126 women who had had full axillary dissection as part of their initial surgical treatment was undertaken to assess their degree of morbidity in terms of numbness, pain, weakness, swelling, and stiffness. Seventy per cent of cases complained of numbness, 33% of pain, 25% of weakness, 24% of limb swelling, and 15% of stiffness. Objective measurements confirmed decreased sensation in 81%, weakness in 27%, swelling in 10%, and stiffness in 10%. In no case were these symptoms described as severe, though they did have an effect upon the daily lives of 39%. The side effects of full axillary dissection are common and all women should be warned of them prior to surgery; however they are usually mild and therefore should not preclude this procedure as a part of definitive surgical treatment.

Entities:  

Mesh:

Year:  1992        PMID: 1637663      PMCID: PMC1977908          DOI: 10.1038/bjc.1992.230

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

Review 1.  The axilla: not a no-go zone.

Authors:  I S Fentiman; R E Mansel
Journal:  Lancet       Date:  1991-01-26       Impact factor: 79.321

2.  Post-axillary dissection pain in breast cancer due to a lesion of the intercostobrachial nerve.

Authors:  C J Vecht; H J Van de Brand; O J Wajer
Journal:  Pain       Date:  1989-08       Impact factor: 6.961

3.  Usefulness and technique of axillary dissection in primary breast cancer.

Authors:  B Cady; H F Sears
Journal:  J Clin Oncol       Date:  1986-05       Impact factor: 44.544

4.  Number of lymph nodes examined and the prognosis of breast carcinoma.

Authors:  B Fisher; N H Slack
Journal:  Surg Gynecol Obstet       Date:  1970-07

5.  The inadequacy of axillary sampling in breast cancer.

Authors:  M W Kissin; E M Thompson; A B Price; G Slavin; A E Kark
Journal:  Lancet       Date:  1982-05-29       Impact factor: 79.321

6.  Postoperative lymphoedema after treatment of breast cancer.

Authors:  B Brismar; I Ljungdahl
Journal:  Acta Chir Scand       Date:  1983

7.  Sequelae of axillary dissection vs. axillary sampling with or without irradiation for breast cancer. A randomized trial.

Authors:  S Borup Christensen; E Lundgren
Journal:  Acta Chir Scand       Date:  1989-10

8.  Arm morbidity within a trial of mastectomy and either nodal sample with selective radiotherapy or axillary clearance.

Authors:  R J Aitken; M N Gaze; A Rodger; U Chetty; A P Forrest
Journal:  Br J Surg       Date:  1989-06       Impact factor: 6.939

9.  Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla.

Authors:  H P Graversen; M Blichert-Toft; J A Andersen; K Zedeler
Journal:  Eur J Surg Oncol       Date:  1988-10       Impact factor: 4.424

10.  Risk of lymphoedema following the treatment of breast cancer.

Authors:  M W Kissin; G Querci della Rovere; D Easton; G Westbury
Journal:  Br J Surg       Date:  1986-07       Impact factor: 6.939

View more
  72 in total

Review 1.  Axillary staging of breast cancer and the sentinel node.

Authors:  G Cserni
Journal:  J Clin Pathol       Date:  2000-10       Impact factor: 3.411

2.  Intraoperative touch imprint cytology of sentinel lymph nodes in breast cancer: experience at a tertiary care center in Mexico.

Authors:  V M Pérez-Sánchez; T A Vela-Chávez; P Villarreal-Colin; E Bargalló-Rocha; M T Ramírez-Ugalde; D Munoz-Gonzalez; I Zeichner-Gancz
Journal:  Med Oncol       Date:  2009-03-19       Impact factor: 3.064

3.  Intraoperative assessment of sentinel node using imprint cytology.

Authors:  Dayalan Clarke; Edmund Leung; Naresh Chachlani; David Rowlands; Jayanthi Simon; Isabel Hero; David England
Journal:  World J Surg       Date:  2010-01       Impact factor: 3.352

4.  Complications of level I and II axillary dissection in the treatment of carcinoma of the breast.

Authors:  D F Roses; A D Brooks; M N Harris; R L Shapiro; J Mitnick
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

5.  Survival analysis following sentinel lymph node biopsy: a validation trial demonstrating its accuracy in staging early breast cancer.

Authors:  John T Carlo; Michael D Grant; Sally M Knox; Ronald C Jones; Cody S Hamilton; Sheryl A Livingston; Joseph A Kuhn
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-04

6. 

Authors:  J C Rageth
Journal:  Arch Gynecol Obstet       Date:  1995-12       Impact factor: 2.344

7.  A pilot randomized trial evaluating low-level laser therapy as an alternative treatment to manual lymphatic drainage for breast cancer-related lymphedema.

Authors:  Sheila H Ridner; Ellen Poage-Hooper; Collin Kanar; Jennifer K Doersam; Stewart M Bond; Mary S Dietrich
Journal:  Oncol Nurs Forum       Date:  2013-07       Impact factor: 2.172

8.  Physical Activity and Lymphedema (the PAL trial): assessing the safety of progressive strength training in breast cancer survivors.

Authors:  Kathryn H Schmitz; Andrea B Troxel; Andrea Cheville; Lorita L Grant; Cathy J Bryan; Cynthia R Gross; Leslie A Lytle; Rehana L Ahmed
Journal:  Contemp Clin Trials       Date:  2009-01-08       Impact factor: 2.226

9.  Intraoperative imprint cytologic evaluation of sentinel lymph nodes for lobular carcinoma of the breast.

Authors:  Andrew J Creager; Kim R Geisinger; Nancy D Perrier; Perry Shen; Jo Ann Shaw; Peter R Young; Doug Case; Edward A Levine
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

10.  Pre-operative assessment enables early diagnosis and recovery of shoulder function in patients with breast cancer.

Authors:  Barbara A Springer; Ellen Levy; Charles McGarvey; Lucinda A Pfalzer; Nicole L Stout; Lynn H Gerber; Peter W Soballe; Jerome Danoff
Journal:  Breast Cancer Res Treat       Date:  2010-02       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.